COMMUNIQUÉS West-GlobeNewswire

Tauriga Sciences Inc. Formally Cancels All Remaining Back-End Convertible Debentures Held by Adar Bays LLC in Connection with the $210,000 Financing Agreement from September 2017

16/04/2018 - 18:24

NEW YORK, NY, April 16, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTC PINK: TAUG ) ("Tauriga" or the "Company"), engaged in building its business through the development, distribution, and licensing of [...]

Ossur Hf : Transactions in relation to share buyback program

16/04/2018 - 18:01

Announcement no. 29/2018 Reykjavik, 16 April 2018 Transactions in relation to share buyback program On 5 March 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 16/2018. The purpose of the [...]

FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself

16/04/2018 - 17:31

FIT Biotech Oy Company release April 16, 2018 at 6:30 pm EET FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself FIT Biotech Oy's Board of Directors has [...]

Sienna Announces Q1 2018 Results Release Date and Conference Call

16/04/2018 - 17:03

MARKHAM, Ontario, April 16, 2018 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA ) announced that it will report its 2018 first quarter results after market close on Thursday, May [...]

Addus HomeCare Announces First-Quarter 2018 Earnings Release and Conference Call

16/04/2018 - 17:00

Frisco, Texas, April 16, 2018 (GLOBE NEWSWIRE) -- Addus HomeCare Corporation (NASDAQ: ADUS), a provider of comprehensive home care services, announced today that it will release earnings for the first quarter ended [...]

Innovation Pharmaceuticals Data from Phase 2 Brilacidin Oral Mucositis (OM) Trial in Head and Neck Cancer Show Notable Reductions in Median Duration of Severe OM and in Number of Unplanned Visits/Hospital Admissions Due to OM

16/04/2018 - 16:45

Median Duration of Severe Oral Mucositis (SOM) Reduced to Less Than One Day No Unplanned Office Visits, Emergency Department Visits, and/or Hospital Admissions Due to OM in Brilacidin-OM Arm vs. Four in Placebo Arm Data [...]

California Proposes Bills to Outlaw Self-Determination in Medical Therapy, Reports the Association of American Physicians and Surgeons (AAPS)

16/04/2018 - 16:22

TUCSON, Ariz., April 16, 2018 (GLOBE NEWSWIRE) -- Three bills moving rapidly through the California legislature threaten to outlaw certain treatments that may be offered by physicians or other therapists, or sought by [...]

Nelipak Healthcare Packaging Announces Freestanding Rotary Medical Tray and Blister Heat Sealers

16/04/2018 - 16:15

Machine Portfolio Also Includes Enhanced PLC Controlled and Analog Sealers CRANSTON, R.I., April 16, 2018 (GLOBE NEWSWIRE) -- Nelipak ® Healthcare Packaging (“Nelipak”), a full-service global provider of custom [...]

PolarityTE Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option

16/04/2018 - 16:00

SALT LAKE CITY, April 16, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq: COOL ), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, [...]

Photocure ASA: Annual accounts 2017

16/04/2018 - 15:52

Oslo, 16 April 2018: Photocure ASA (OSE: PHO), has published the annual accounts and annual report for the financial year 2017. The annual accounts and annual report for the financial year 2017 are enclosed with this [...]

Photocure ASA: Notice of the annual general meeting 9 May 2018

16/04/2018 - 15:45

Oslo, 16 April 2018: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Hoffsveien 4, 1 st floor, 0275 Oslo, Norway on 9 May 2018 at 17:00 hours (CET). The notice convening the general [...]

Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab

16/04/2018 - 15:23

Interim data shows broad hematologic correction including improved hemoglobin levels and reduction in LDH CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS [...]

Novo Nordisk A/S - Share repurchase programme

16/04/2018 - 15:18

Bagsværd, Denmark, 16 April 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 [...]

New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform

16/04/2018 - 15:05

Preclinical Data Presented at AACR Highlight the Novel Mechanism of Action Underscoring the Company’s T cell-Activating Technology HALIFAX, Nova Scotia, April 16, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV [...]

Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release

16/04/2018 - 15:02

New Preclinical Data Presented at the 2018 American Association for Cancer Research Annual Meeting Show Potent T-Cell Directed Tumor Killing with Reduced Cytokine Production Compared to a Competitor Bispecific Construct [...]

OrthoPediatrics Corp. Honored as One of the Best Places to Work in Indiana for a Second Year

16/04/2018 - 15:00

WARSAW, Ind., April 16, 2018 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (NASDAQ: KIDS ), a company exclusively focused on advancing the field of pediatric orthopedics, is pleased to announce that it was recently named as [...]

Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting

16/04/2018 - 15:00

CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ: LPTX ) today presented nonclinical and clinical data on DKN-01, Leap’s anti-DKK1 monoclonal antibody, at the American Association for [...]

Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors

16/04/2018 - 15:00

EAGAN, Minn., April 16, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced the presentation of new translational data from ongoing phase 2 clinical trials combining Biothera’s Imprime PGG with [...]

TESARO Summarizes TSR-042 Clinical Data Presented at AACR

16/04/2018 - 15:00

Activity of TSR-042 (anti-PD-1 antibody) monotherapy demonstrated in patients with MSI-high endometrial and non-small cell lung cancers Data support unique and convenient dosing schedule Regulatory submission for TSR- [...]